Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18;~* Patients who have undergone hematopoietic stem cell transplantation (HSCT);~* Patients who don't take any drug including Eltrombopag and rhTPO before hematopoietic stem cell transplantation (HSCT);~* Patients receiving either an autologous (Auto) or allogeneic (Allo) stem cell transplantation from a sibling,related donor, or matched unrelated donor are included;~* Agree to sign informed consent~Exclusion Criteria:~* Patients with thrombocytopenia causes by other reasons, such as drugs, cytomegalovirus or infection;~* Patients who had greater risk of thromboembolic disease within six months;~* Patients with a history of heart disease;~* Patients with severe organ dysfunction;~* Patients with other malignancies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): Thrombopoietin- receptor (TPO-R) agonist
- rhTPO (Type: PLACEBO_COMPARATOR): Recombinant human thrombopoietin (rhTPO)

Based on this trial design, predict the completion outcome and termination type (if applicable).